Comparative Pharmacology
Head-to-head clinical analysis: STADOL versus ZYDONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STADOL versus ZYDONE.
STADOL vs ZYDONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Partial agonist at mu-opioid receptors and agonist at kappa-opioid receptors in the CNS, altering pain perception and emotional response to pain.
Hydrocodone is a mu-opioid receptor agonist; acetaminophen produces analgesia via central COX inhibition and activation of descending serotonergic pathways.
Butorphanol tartrate 1-2 mg IV or IM every 3-4 hours as needed for pain; alternatively, 0.5-1 mg IV every 3-4 hours. For nasal spray: 1 mg (one spray) in one nostril, may repeat in 60-90 minutes if needed; then 1 mg every 3-4 hours as needed.
Oral: 1 to 2 tablets every 4 to 6 hours as needed for pain. Each tablet contains hydrocodone bitartrate 5 mg and acetaminophen 500 mg (Zydone 5/500). Maximum acetaminophen dose: 4000 mg/day (8 tablets).
None Documented
None Documented
Terminal elimination half-life: 2.5-4 hours; clinically, prolonged in hepatic impairment (up to 10-12 hours) and elderly
Terminal elimination half-life of hydrocodone is 3.8-4.5 hours in healthy adults; prolonged in elderly or hepatic impairment (up to 6-8 hours). Clinical context: dosing interval typically every 4-6 hours, adjusted for renal/hepatic insufficiency.
Renal: 85-90% as unchanged drug and metabolites (primarily as glucuronide conjugates); Fecal: <10%; Biliary: minimal
Approximately 60% of hydrocodone and its metabolites are excreted renally as glucuronide conjugates; ~10% as norhydrocodone, hydromorphone, and other metabolites. Fecal excretion accounts for less than 5%. Total renal elimination: ~65-70%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic